NY-XANDR
27.10.2021 14:02:06 CEST | Business Wire | Press release
Xandr , AT&T’s advanced advertising company, today announced investments which expand its portfolio of identity offerings. Earlier this year, Xandr announced a multi-faceted approach to balance customers’ advertising needs and consumer privacy, and has now delivered several addressability solutions through integrations with LiveRamp (NYSE:Ramp), netID and Unified ID 2.0, as well as publisher first-party data activation solutions, contextual and modelled capabilities.
Facilitating addressability through consumer-consented data is a key component that Xandr has made strides on. Through Xandr’s collaboration with LiveRamp, Xandr this year launched end-to-end support for RampID on its platform. Publishers using Xandr’s Monetize SSP have started to use RampIDs in their monetization strategies and have seen positive indications. Agencies and marketers are also beginning alpha tests for RampID capabilities on Xandr’s Invest DSP, which include data onboarding, targeting and measurement. Xandr and LiveRamp are also expanding their relationship in other ways, including LiveRamp becoming a partner on Xandr Curate, the platform for monetizing data through curated deals. Travis Clinger, SVP, addressability and ecosystem at LiveRamp comments: “Our mission has always been to make it safe and easy for our partners and customers to connect data, wherever data lives. Our continued and evolving partnership with Xandr helps make that possible programmatically, bringing the demand- and sell-sides closer together to ensure critical advertising workflows are more sustainable, efficient, and performant on a global scale. Further, Xandr's support of RampID, a high-fidelity, person-level, omnichannel identifier, takes our existing integration with them to the next level.”
First-party data will be key in the new era of advertising. Xandr has laid the foundation to roll out a suite of powerful tools which empower publishers to leverage their data assets to power relevant advertising, while still protecting the privacy needs of their users. Xandr’s publisher first-party data capabilities provide the necessary targeting, frequency management and privacy controls to enable scaled monetization across environments. Today, Xandr supports netID across multiple use cases, and continues to build upon this investment, working with netID, publishers and marketers on its platform. In 2022, Xandr will launch an enhanced Publisher ID suite providing additional capabilities, which is built to address publishers’ forward-looking needs. “ Providing publishers with the right tools to successfully execute business models, while ensuring that data is properly protected and users are in full control, will be of the utmost importance in this transformational shift in advertising”, says Achim Schlosser, CTO of the European netID Foundation. “First-party data is a key building block in future of digital marketing, which needs to be both user-friendly and sustainable. For that we need strong co-operation among the industry to enable a fair and open web.”
Whilst LiveRamp and netID integrations are complete, Xandr is collaborating with the industry to ensure readiness for the broader launch of the Unified ID 2.0 integration.
Alongside these integrations Xandr has advanced its modelled and contextual solutions utilizing data science, machine learning, and contextual data to enable relevant advertising in the absence of identifiers.
Xandr has been productizing its Real Time Signals offering (RTS) which enables audience activation by using contextual signals such as hyperlocal geolocation and URL to reach audiences in identity-less environments. RTS is a differentiating, scalable way to reach our clients’ desired customers in a privacy compliant manner and Xandr recently showcased this through its work with Dentsu .
Frequency management to avoid over-exposure is a critical need for publishers and marketers. As such, Xandr has developed an inventory classification model which does not rely on cookies or device/user level identifiers. This enables Xandr to infer one brand’s ad exposure to a user based on averages in real-time and make decisions on whether or not to bid for an impression, thereby enabling platform customers to prevent consumer ad fatigue and wasted spend without reliance on user identifiers.
Xandr understands that collaboration in the industry is the best approach to solving identity. With this in mind Xandr participated in the Google FLoC trial in June and July to better understand the solution. Xandr is continuing to work across industry groups to refine and test other proposals within this, including PARAKEET.
“Xandr is focused on the development of alternative solutions for its clients. Whilst integrations are an important part of this, as is first-party data activation solutions, Xandr is also heavily focused on offering modelled and contextual solutions of its own. During this time Xandr has also been working with customers on different testing opportunities and on Xandr’s platform, buyers and sellers are now able to target, frequency cap and measure outcomes” adds Ewa Maciukiewicz, VP, Product Management, Xandr. “Whilst there is no simple solution to identity, looking ahead to 2022 Xandr is focused on scaling addressability, simplifying first-party data activation, accelerating the connection between marketers and publishers, and thinking beyond identity to drive relevant advertising in non-addressable environments.”
ABOUT XANDR
A business unit within AT&T, Xandr powers a global marketplace for premium advertising. Our data-enabled technology platform, encompassing Xandr Invest and Xandr Monetize, optimizes return on investment for both buyers and sellers. For more than 143 years, AT&T has used data and technology to inform and improve the consumer experience.
ABOUT LiveRamp
LiveRamp is the leading data connectivity platform for the safe and effective use of data. Powered by core identity resolution capabilities and an unparalleled network, LiveRamp enables companies and their partners to better connect, control, and activate data to transform customer experiences and generate more valuable business outcomes. LiveRamp’s fully interoperable and neutral infrastructure delivers end-to-end addressability for the world’s top brands, agencies, and publishers. For more information, visit www.LiveRamp.com
ABOUT EUROPEAN NETID FOUNDATION
The European netID Foundation was founded in March 2018 by Mediengruppe RTL Deutschland, ProSiebenSat.1 and United Internet with the brands WEB.DE and GMX. With an independent market solution, the foundation supports Internet offerings of all industries in implementing the new European data protection law and has created the open login standard netID for this purpose. The initiators of the foundation together reach around 50 million unique users every month and together have more than 38 million active accounts. The foundation is explicitly open for further partners and other initiatives. Further information is available at www.enid.eu .
“We are proud that our netID identifier is supported by Xandr’s end-to-end platform. This gives content providers in Europe the possibility to easily deliver personalized advertising in compliance with data protection regulations and across devices,” says Sven Bornemann, CEO of the European netID Foundation. “As well, we are very much looking forward to our partnership and warmly welcome Xandr’s Thomas Mendrina to the Publishing/Ad Sales advisory board of the European netID Foundation.”
ABOUT UNIFIED ID 2.0
Unified ID 2.0 is a next-generation identity solution that is an open-source digital framework. With initial development led by The Trade Desk, Unified ID 2.0 is the result of broad collaboration among publishers, buyers and technology providers across the industry. It serves as an alternative to third-party cookies that aims to improve consumer transparency, privacy and control, while preserving the value exchange of relevant advertising across channels and devices.
Prebid.org, the independent organization designed to ensure and promote fair and transparent marketplaces across the industry, has agreed to serve as operator of Unified ID 2.0. Prebid.org will begin this role in the second half of this year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005390/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
